Market Overview

UPDATE: Jefferies Downgrades GlaxoSmithKline to Hold on Margin Expansion Visibility

Share:
Related GSK
Believe It: Brexit Isn't All Bad For U.K. ETFs
5 Stocks Cut In Half In 2016
Wall Street Breakfast: Earnings Season Kicks Into High Gear (Seeking Alpha)

Jefferies cut its rating on GlaxoSmithKline (NYSE: GSK) from Buy to Hold on reduced visibility to the company's margin expansion.

Jefferies commented, "Whilst we still see double digit CORE EPS growth for GlaxoSmithKline from 2013E-17E, visibility on margin expansion has been obscured by over-exposure to price pressure and transfer pricing in Europe. The shares have recovered well from their lows since the Q2'12 results and we take this opportunity to cut our rating to Hold from Buy given the limited upside."

GlaxoSmithKline closed at $46.84 on Friday.

Latest Ratings for GSK

DateFirmActionFromTo
Jul 2016JefferiesUpgradesHoldBuy
Feb 2016Cantor FitzgeraldInitiates Coverage onHold
Jan 2016Bryan GarnierUpgradesNeutralBuy

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (GSK)

View Comments and Join the Discussion!